NIROGY THERAPEUTICS
Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.
NIROGY THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2013-01-01
Address:
Natick, Massachusetts, United States
Country:
United States
Website Url:
http://www.nirogytx.com
Total Employee:
1+
Status:
Active
Total Funding:
18.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome WordPress 6.0 WP Rocket
Similar Organizations
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Galectin Therapeutics
Galectin Therapeutics uses galectin science and drug development to create new therapies for fibrotic diseases and cancer.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Rigel Pharmaceuticals
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sporos Bioventures
Sporos Bioventures investment in Series A - Nirogy Therapeutics
Sante Ventures
Sante Ventures investment in Series A - Nirogy Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-12 | Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer |
Official Site Inspections
http://www.nirogytx.com Semrush global rank: 5.74 M Semrush visits lastest month: 1.46 K
- Host name: secure.depinhodesign.com
- IP address: 104.247.77.142
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Nirogy Therapeutics"
Nirogy Therapeutics - Crunchbase Company Profile & Funding
View contacts for Nirogy Therapeutics to access new leads and connect with decision-makers. Nirogy Therapeutics is a biotechnology company developing novel small molecules to target …See details»
Nirogy Therapeutics - VentureRadar
Website: https://nirogytx.com. Develops innovative tumor-targeting small molecules for precision cancer therapy, focusing on improved efficacy and reduced side effects. VentureRadar …See details»
Nirogy Therapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Nirogy Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Nirogy Therapeutics - Overview, News & Similar companies
Apr 7, 2021 · Nirogy Therapeutics contact info: Phone number: (508) 506-9006 Website: www.nirogytx.com What does Nirogy Therapeutics do? Based in Boston, MA, Nirogy …See details»
Nirogy Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Www.nirogytx.com. Last update 19 Sep 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The statistics for …See details»
Nirogy Therapeutics - Craft
See insights on Nirogy Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Nirogy Therapeutics - Products, Competitors, Financials, …
Nirogy Therapeutics is a biotechnology company that develops small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to …See details»
Nirogy Therapeutics Launches with $16.5 Million Series A Financing
BOSTON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today …See details»
We are excited to announce that Nirogy Therapeutics, Inc. has
Jan 12, 2022 · We are excited to announce that Nirogy Therapeutics, Inc. has named a new CEO, industry leader, Simon C. Pedder, Ph.D. Do you have an interest in cutting edge science? We …See details»
Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief …
Jan 12, 2022 · Nirogy Therapeutics today announced that it has appointed life science veteran Simon Pedder, Ph.D., as Chief Executive Officer (CEO) and to the Company’s Board of …See details»
Nirogy Therapeutics to Present at AACR Annual Meeting 2022
Apr 4, 2022 · Nirogy Therapeutics is a biotechnology company based in Boston, MA, developing novel small molecules to target cellular transporters. The company is currently advancing a …See details»
Nirogy Therapeutics Launches with $16.5 Million Series A
Jan 26, 2021 · Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the closing of a $16.5 million …See details»
Nirogy Therapeutics | VentureRadar
Website: https://nirogytx.com. Develops innovative tumor-targeting small molecules for precision cancer therapy, focusing on improved efficacy and reduced side effects. VentureRadar …See details»
Series A - Nirogy Therapeutics - 2021-01-26 - Crunchbase
Nirogytx.com — Nirogy Therapeutics Launches with $16.5 Million Series A FinancingSee details»
Nirogy Therapeutics Launches with $16.5 Million Series A Financing
January 26, 2021 – Nirogy Therapeutics Inc ., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the closing of a $16.5 …See details»
Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief …
Jan 12, 2022 · Nirogy Therapeutics is a biotechnology company based in Boston, MA developing novel small molecules to target cellular transporters. The company is currently advancing a …See details»
Vincent Sandanayaka - Founder & President, CSO at Nirogy
Get the details of Vincent Sandanayaka's business profile including email address, phone number, work history and more.See details»
Nirogy Therapeutics to Present at AACR Annual Meeting 2021
Apr 7, 2021 · E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous …See details»
Nirogy Therapeutics Launches with $16.5 Million Series A
BOSTON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today …See details»
Nirogy Therapeutics to Present at AACR Annual Meeting 2021
E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of …See details»